PTPA and alpha 1-antitrypsin deficiency: As a result of augmented PP2A activation by AAT, BALF samples from AAT deficiency individuals undergoing supplementation AAT therapy had significantly reduced levels of MMP-1, MMP-9, IL-8, IL-1β, MCP-1, and TNF-α.